


Substitute for Form PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 012679-113 U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/552291 Unassigned
INTERNATIONAL APPLICATION NO. PCT/KR2004/000774	INTERNATIONAL FILING DATE 2 April 2004 (02.04.2004)	PRIORITY DATE CLAIMED 3 April 2003 (03.04.2003)
TITLE OF INVENTION USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA 3 INTEGRIN OF ENDOTHELIAL CELL		
APPLICANT(S) FOR DO/EO/US Ju-Ock NAM, Jung-Eun KIM, Ha-Won JEONG, Sung-Jin LEE, Byung-Heon LEE, Je-Yong CHOI, Ran-Woon PARK, Jae-Yong PARK and In-San KIM		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a FIRST submission to items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 21 below concern document(s) or information included: 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: <u>1) Application Data Sheet; 2) General Authorization for Petitions for Extensions of Time and Payment of Fees; 3) Paper copy of Sequence Listing (attached to Preliminary Amendment); 4) Declaration Pursuant to 37 CFR Sections 1.821-1.825; 5) Forms PCT/ISA/202 (PCT Request), PCT/ISA/210 (Int'l Search Report), PCT/ISA/237, PCT/IB/301, PCT/IB/304, PCT/IB/308, PCT/IB/311, PCT/IB/332, PCT/IPEA/401, PCT/IPEA/402, PCT/IPEA/416 and PCT/IPEA/409.</u>		

U.S. APPLICATION NO. <u>10/552294</u> Unassigned		INTERNATIONAL APPLICATION NO. PCT/KR2004/000774		ATTORNEY'S DOCKET NUMBER 012679-113	
---	--	--	--	--	--

21. <input checked="" type="checkbox"/> Applicant(s) requests that the published application include the following assignment information: <u>REGEN BIOTECH, INC., Seoul, Republic of Korea.</u> 	CALCULATIONS PTO USE ONLY.
--	-----------------------------------

22. <input checked="" type="checkbox"/> The following fees are submitted:						
Basic Filing Fee (1631)				\$ 300.00		
Surcharge of \$130.00 (1617) for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
Total Claims	12	-20 =	0	x \$50.00 (1615)	\$ 0.00	
Independent Claims	6	-3 =	3	x \$200.00 (1614)	\$ 600.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$360.00 (1616)		
Examination Fee				+ \$200.00 (1633)	\$ 200.00	
Search Fee				+ \$500.00 (1632)	\$ 500.00	
App. Size Fee (add \$250.00 for each add'l 50 sheets exceeding 100 sheets)						
TOTAL OF ABOVE CALCULATIONS =					\$ 1,600.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	\$ 800.00	
SUBTOTAL =					\$ 800.00	
Processing fee of \$130.00 (1618) for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					\$ 0.00	
TOTAL NATIONAL FEE =					\$ 800.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (8021) per property +					\$ 40.00	
TOTAL FEES ENCLOSED =					\$ 840.00	
				Amount to be refunded :		
				charged :		
a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed.						
b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.						
d. <input checked="" type="checkbox"/> Charge <u>\$ 840.00</u> to credit card. Form PTO-2038 is attached.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						
SEND ALL CORRESPONDENCE TO: Burns, Doane, Swecker & Mathis, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620						
				 SIGNATURE		
				Susan M. Dadio NAME		
				<u>40,373</u> REGISTRATION NO.	<u>October 3, 2005</u> DATE	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Ju-Ock Nam et al.

Group Art Unit: Unassigned

Application No.: Unassigned

Examiner: Unassigned

Filing Date: October 3, 2005

Confirmation No.: Unassigned

Title: USE OF A PEPTIDE THAT INTERACTS WITH ALPHA V BETA 3 INTEGRIN OF ENDOTHELIAL CELL

GENERAL AUTHORIZATION FOR PETITIONS
FOR EXTENSIONS OF TIME AND PAYMENT OF FEES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.136(a)(3), the U.S. Patent and Trademark Office is hereby provided with a general authorization to treat any concurrent or future reply requiring a petition for an extension of time for its timely submission as containing a request therefor for the appropriate length of time.


The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.17 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By


Susan M. Dadio
Registration No. 40,373

Date: October 3, 2005